Tag
A multicenter RCT demonstrates remote blood pressure monitoring reduces antenatal visits and hospital admissions without compromising maternal or fetal outcomes in women at high risk of preeclampsia.
Escalation of antihypertensive treatment in expectant management of early-onset preeclampsia with severe features correlates with increased maternal adverse outcomes, suggesting treatment trajectory as a dynamic risk indicator.
Large-scale proteomic analysis identifies novel maternal plasma protein biomarkers that improve detection of fetal death beyond established markers, highlighting both shared and unique pathological pathways with preeclampsia.
In women with chronic hypertension, fetal growth restriction at 35-36 weeks gestation predicts higher progression to superimposed preeclampsia, underscoring the need for targeted maternal-fetal surveillance.
Universal dispensation of aspirin at 162 mg daily in high-risk pregnant populations reduces preeclampsia with severe features without increasing adverse maternal or neonatal outcomes, supporting broad aspirin use beyond risk-based prescribi
This study delineates the significant recurrence risk of severe hypertensive disorders of pregnancy, especially early-onset cases, highlighting implications for patient counseling and management in subsequent pregnancies.
This study elucidates how uterine artery Doppler at 35-36 weeks reflects placental angiogenic imbalance and hemodynamic dysfunction in preeclampsia, underscoring its biological relevance beyond early pregnancy screening.
This review synthesizes evidence linking ischemic placental disease—comprising preeclampsia, placental abruption, and fetal growth restriction—with increased postpartum maternal risk of neurological and psychiatric hospitalizations within o
This review synthesizes evidence on the cost-effectiveness of the FMF first-trimester screening strategy for preterm preeclampsia in the UK compared to NICE recommendations, highlighting clinical efficacy, economic benefits, and implication
Unsupervised machine learning identified three distinct preeclampsia phenotypes linked to timing of delivery, placental dysfunction, fetal growth, and complications, suggesting a path toward more personalized risk assessment and management.
Higher proteinuria in preeclampsia was linked to greater long-term risk of maternal hypertension and chronic kidney disease, with overall increased risk of cardiovascular disease as well.
A nationwide study reveals that eclampsia patients face a 6.9-fold increased risk of cardiovascular disease readmission within the first year postpartum, with stroke risk nearly 13 times higher than normotensive patients. These findings und
This article examines a comprehensive study on the effectiveness of the USPSTF preeclampsia risk assessment guidelines and the implementation of aspirin prophylaxis in modern obstetric care.
The POP-HT randomized clinical trial imaging substudy demonstrates that intensive postpartum blood pressure management after hypertensive pregnancy is associated with significantly larger white matter and subcortical brain volumes, suggesti
A large-scale analysis of over 115,000 patients demonstrates that isolated severe systolic hypertension (SBP ≥160 mmHg) during delivery admission is independently associated with a dramatic, dose-dependent increase in severe maternal morbid
Genetic predisposition to preeclampsia and gestational hypertension is associated with higher risk of later-life cardiovascular disease; polygenic risk amplifies this risk, while obstetric history improves risk stratification beyond PRSs al
This RCT compares nifedipine GITS 30 mg twice daily versus 60 mg once daily in severe preeclampsia, finding similar blood pressure control but fewer emergent treatments with twice-daily dosing, informing safer antihypertensive strategies in
This article explores how microcirculation functions as a key regulator in normal pregnancy but is compromised in preeclampsia, revealing early hemodynamic mechanisms behind gestational hypertension.
A recent study questions the specificity of USPSTF guidelines for preeclampsia risk assessment, highlighting challenges in identifying patients truly at high risk and ensuring targeted aspirin prophylaxis.
DM199 has demonstrated safety and efficacy in reducing blood pressure among preeclampsia patients during a Phase 2 trial, offering hope for improved maternal and fetal outcomes.
